Business Wire

Areteia Therapeutics Announces Appointment of Elyse Stock, M.D. To Board of Directors

Share

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Elyse Stock, M.D. to the Areteia Board of Directors, effective April 17, 2023. Dr. Stock will serve as a member of the compensation, nominating and corporate governance committee of the board.

“I am excited that Elyse has been appointed to our board,” said Jorge Bartolome, Chief Executive Officer of Areteia. “She is an incredibly accomplished executive whose depth of experience, proven leadership and scientific expertise will be invaluable to the leadership team and the Board of Directors as we focus on delivering on the Company’s strategy and further advancing the Phase III program for dexpramipexole, the first potential oral drug for eosinophilic asthma.”

Commenting on her appointment, Dr. Stock said, “I am honored to serve as a director and look forward to working with Jorge and the team. This is a compelling opportunity to address a high unmet need for severe asthmatics by potentially bringing the first oral medicine to market to treat eosinophilic asthma earlier in the treatment paradigm and offer patients and health systems an alternative to injectable biologics.”

Dr. Stock brings to her role a distinguished 36-year track record of clinical and drug development experience. After practicing psychiatry for 11 years she joined the pharmaceutical industry. Dr. Stock spent the last six years at Biohaven Pharmaceuticals where she was the CMO responsible for the development of numerous investigational agents including NURTEC® and was integral in transitioning that franchise to Pfizer after its acquisition. Prior to Biohaven, she spent 19 years at Bristol-Myers Squibb developing numerous experimental agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular. She has led numerous large and complex programs across all aspects of development including those leading to the marketing of products such as ABILIFY®, ORENCIA®, and EMPLICITI®. She is an experienced developer of both biologic and non-biologic compounds.

Dr. Stock completed her residency at Payne Whitney Clinic, Cornell Medical Center and her fellowship in Child and Adolescent Psychiatry at Children’s Hospital National Medical Center in Washington D.C. She earned her medical degree at New York University School of Medicine.

About Areteia Therapeutics

Areteia Therapeutics, Inc. (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor.

Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase III clinical trials, secure commercial supply, and pursue potential next-generation medicines.

Areteia has initiated late-stage development of dexpramipexole in eosinophilic asthma, including three Phase III clinical trials in partnership with Population Health Partners’ development unit, Validae Health.

About Dexpramipexole

Dexpramipexole is an oral small molecule in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (daily dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.

About Eosinophilic Asthma

Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tamsin Berry
Tamsin.Berry@areteiatx.com

Mark Kreston
Mark.Kreston@areteiatx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BYD Unleashes FANG CHENG BAO, A New Brand that Specializes in Professional and Personalized Identities9.6.2023 06:41:00 EEST | Press release

On June 9, BYD, the world’s leading manufacturer of new energy vehicles, officially announced its new sub-brand FANG CHENG BAO. The brand, as the fifth in the row of the BYD brand matrix, will meet the increasingly personalized needs of consumers by offering a series of unique and professional-grade new energy vehicle models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005841/en/ SF (Photo: Business Wire) FANG CHENG BAO is a significant addition to BYD’s diversified brand matrix, following its Dynasty series, Ocean series, Denza, and Yangwang. The vehicle lineup of FANG CHENG BAO ranges from off-road vehicles to sports cars, and its initial model, a hardcore SUV codenamed SF, is expected to launch this year. The brand name FANG CHENG BAO translates literally as “Formula” and “Leopard” from Chinese, symbolizing the pursuit of the transformative rise and the exploration of digital realms. It blends the standards and r

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia9.6.2023 02:40:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act (PDUFA) target action dates of December 8, 2023, and March 30, 2024, respectively. Updated data from the pivotal trials supporting the regulatory submissions will be presented at the Annual European Hematology Association Congress on June 11, 2023. “We are very pleased with the acceptance of the submissions and the Priority Review designation for SCD by the FDA, as well as the progress of the exa-cel filings in the EU and U.K.,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Exa-

Citi Global Wealth Investments Issues Mid-Year Wealth Outlook 2023 - Opportunities on the Horizon: Investing Through a Slowing Economy9.6.2023 00:59:00 EEST | Press release

Citi Global Wealth Investments today released its Mid-Year Wealth Outlook 2023 report - Opportunities on the Horizon: Investing Through a Slowing Economy. This biannual report sets out Citi Global Wealth’s outlook on how investors should approach developments in the global economy, markets and geopolitics. Though 2023 has been full of extraordinary events, Citi Global Wealth sees the remainder of the year as an opportunity. We are in a “rolling recession” where parts of the US economy are growing even as others contract. As inflation slowly eases following a period of rapid Fed rate hikes, the group believes that keeping portfolios invested is imperative. While the current asset allocation strategy remains defensive, Citi Global Wealth see numerous opportunities to adjust their portfolios over time, as the Fed shifts from interest rate hikes to cuts. We believe that current markets will lead into a meaningful potential recovery in 2024. “Though the broader bear market is not yet over,

Verisign Reports Internet Has 354.0 Million Domain Name Registrations at the End of the First Quarter of 20238.6.2023 23:55:00 EEST | Press release

VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the first quarter of 2023 closed with 354.0 million domain name registrations across all top-level domains (TLDs), an increase of 3.5 million domain name registrations, or 1.0%, compared to the fourth quarter of 2022.1,2 Domain name registrations also increased by 3.5 million, or 1.0%, year over year.1,2 The .com and .net TLDs had a combined total of 174.8 million domain name registrations in the domain name base3 at the end of the first quarter of 2023, an increase of 1.0 million domain name registrations, or 0.6%, compared to the fourth quarter of 2022. The .com and .net TLDs had a combined increase of 0.1 million domain name registrations, or 0.1%, year over year. As of March 31, 2023, the .com domain name base totaled 161.6 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net

Momcozy Introduces the Revolutionary M5 All-in-one Hands-free Breast Pump - Empowering Busy Moms with the Ultimate Maternity Solution8.6.2023 23:00:00 EEST | Press release

Momcozy, the esteemed maternity and baby brand favored by over two million moms worldwide, proudly unveils the revolutionary M5 all-in-one hands-free breast pump. Designed to provide the ultimate pumping experience for busy breastfeeding moms, this cutting-edge device showcases Momcozy's commitment to meeting the needs of mothers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005079/en/ M5 All-in-one Handsfree Breast Pump (Graphic: Business Wire) Renowned for its position as a leader in the North American electric breast pump market, Momcozy distinguishes itself yet again with the M5 all-in-one hands-free breast pump. Driven by a user research team that believes in "cozy designs born from love" and strives to cater to customer needs, Momcozy has conducted extensive interviews with thousands of mothers over the past two years. The team's latest findings highlight "comfort" as the most frequently mentioned req

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom